Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation.
Fibroblast growth factor-2 (FGF2) has been demonstrated to be a promising osteogenic factor for treating osteoporosis. Our earlier study shows that transplantation of mouse Sca-1(+) hematopoietic stem/progenitor cells that are engineered to express a modified FGF2 leads to considerable endosteal/tra...
Main Authors: | Xianmei Meng, David J Baylink, Matilda Sheng, Hongjie Wang, Daila S Gridley, K-H William Lau, Xiao-Bing Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3356341?pdf=render |
Similar Items
-
High NESTIN Expression Marks the Endosteal Capillary Network in Human Bone Marrow
by: Francesca M. Panvini, et al.
Published: (2020-12-01) -
Bone Marrow Endosteal Mesenchymal Progenitors Depend on HIF Factors for Maintenance and Regulation of Hematopoiesis
by: Jlenia Guarnerio, et al.
Published: (2014-06-01) -
Evaluation of hematopoietic cells and myeloid/erythroid ratio in the bone marrow of the pheasant (Phasianus colchicus)
by: Mina Tadjalli, et al.
Published: (2013-06-01) -
The Endosteal Niche in Breast Cancer Bone Metastasis
by: Marie-Therese Haider, et al.
Published: (2020-03-01) -
Constitutive Activation of the Canonical NF-κB Pathway Leads to Bone Marrow Failure and Induction of Erythroid Signature in Hematopoietic Stem Cells
by: Masahiro Marshall Nakagawa, et al.
Published: (2018-11-01)